®®®® SIIA Público

Título del libro: Immunotherapy In Resistant Cancer: From The Lab Bench Work To Its Clinical Perspectives
Título del capítulo: Targeting the STAT6 signaling pathway as a therapy against colon cancer

Autores UNAM:
LUIS IGNACIO TERRAZAS VALDES; SONIA ANDREA LEON CABRERA;
Autores externos:

Idioma:

Año de publicación:
2020
Palabras clave:

Colorectal cancer; Immunotherapy; JAK-STAT mutations; Signal transducer and activator of transcription 6 (STAT6); Targeted therapy


Resumen:

Ongoing evidence suggests that signal transducer and activator of transcription 6 (STAT6) plays a pivotal role in colorectal cancer (CRC) development. Compelling evidence from both man and experimental models shows that STAT6 not only contributes in mediating immune response but is also involved in the pathology associated with disease by altering the epithelial barrier function, promoting the proliferation of intestinal epithelial cells, and regulating the expression of pro-survival and pro-metastatic proteins. These studies have led to the approach of targeting STAT6 as an effective treatment strategy in alleviating CRC. Thus, silencing or hindering STAT6 signaling may strengthen the chemotherapy response with positive effects in the current treatments. Therefore, this chapter describes the role of STAT6 in colorectal cancer biology and their potential as a new therapeutic target for the prevention and treatment of this disease. © 2021 Elsevier Inc. All rights reserved.


Entidades citadas de la UNAM: